Bemcentinib Stocks List
Symbol | Grade | Name | % Change | |
---|---|---|---|---|
AVBP | D | ArriVent BioPharma, Inc. | -1.13 | |
ERAS | F | Erasca, Inc | 2.58 | |
APTO | F | Aptose Biosciences, Inc. | 0.50 |
Related Industries: Biotechnology
Related Stock Lists:
Biopharmaceutical
Cancer
Acute Myeloid Leukemia
Cancer Therapies
NSCLC
Solid Tumors
Antineoplastic Drugs
Bacterial Infections
Cancer Treatment
Clinical Medicine
Colorectal Cancer
Drug Resistant Bacterial Infections
Drugs
Enzymes
Gemcitabine
Hematologic Malignancies
Immunotherapy
Lung Cancer
Medicine
Metastatic Solid Tumors
Symbol | Grade | Name | Weight | |
---|---|---|---|---|
CNCR | D | Loncar Cancer Immunotherapy ETF | 1.71 | |
BTEC | D | Principal Healthcare Innovators Index ETF | 0.12 | |
IWC | C | iShares Microcap ETF | 0.1 | |
IBBQ | B | Invesco Nasdaq Biotechnology ETF | 0.04 | |
BIB | C | ProShares Ultra Nasdaq Biotechnology | 0.03 |
Compare ETFs
Related Industries:
Biotechnology
Related Stock Lists:
Biopharmaceutical
Cancer
Acute Myeloid Leukemia
Cancer Therapies
NSCLC
Solid Tumors
Antineoplastic Drugs
Bacterial Infections
Cancer Treatment
Clinical Medicine
Colorectal Cancer
Drug Resistant Bacterial Infections
Drugs
Enzymes
Gemcitabine
Hematologic Malignancies
Immunotherapy
Lung Cancer
Medicine
Metastatic Solid Tumors
- Bemcentinib
Bemcentinib, also known as BGB324 or R428, is an experimental oral small molecule that is an inhibitor of AXL kinase. Bemcentinib was licensed from Rigel Pharmaceuticals by BerGenBio and currently undergoing six Phase II trials in various solid and hematological tumors as monotherapy and in combination with immunotherapy, chemotherapy, and targeted therapeutics.
Popular Now
Recent Comments
- TraderMike on New Scans: Strong, Oversold Stocks and Weak, Overbought Stocks
- ZealousTrout235 on New Scans: Strong, Oversold Stocks and Weak, Overbought Stocks
- TraderMike on Market Recap for Tuesday, May 21, 2024
- CharmingMole371 on Market Recap for Tuesday, May 21, 2024
- TraderMike on IZM
From the Blog
Featured Articles